Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR25617932

— · A

1dcaf9ba-71b8-51c9-a929-00794ef90261

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PANCREAS_BETA_CELLS+0.360
  • MYOGENESIS+0.310
  • KRAS_SIGNALING_DN+0.270
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.240
  • UV_RESPONSE_DN+0.220
  • TNFA_SIGNALING_VIA_NFKB+0.200
  • COAGULATION+0.190
  • ESTROGEN_RESPONSE_EARLY+0.190
  • HEDGEHOG_SIGNALING+0.170
  • WNT_BETA_CATENIN_SIGNALING+0.170

Top 10 suppressed

  • E2F_TARGETS-0.600
  • G2M_CHECKPOINT-0.590
  • MYC_TARGETS_V1-0.530
  • MTORC1_SIGNALING-0.490
  • ALLOGRAFT_REJECTION-0.480
  • MYC_TARGETS_V2-0.450
  • INTERFERON_GAMMA_RESPONSE-0.380
  • PROTEIN_SECRETION-0.340
  • IL6_JAK_STAT3_SIGNALING-0.330
  • UNFOLDED_PROTEIN_RESPONSE-0.330

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1313113
breast-umap@18
—A0.917
2GSM6454739
breast-umap@18
—A0.905
3C3L-01890
lung-landscapes@6
—cohortA20.903
4s0095205
melanoma-umap@29
——0.901
5SRR35579814
breast-umap@18
—A0.901
6SRR1405485
brain-umap@2
GTEX—0.879
7SRR8613796
breast-umap@18
—A0.876
8TCGA-HN-A2OB-01A-21R-A27Q-07
breast-umap@18
—A0.876
9TCGA-AC-A3W7-01A-11R-A22K-07
breast-umap@18
—A0.870
10TCGA-56-8624-01A-11R-2403-07
lung-landscapes@6
—cohortSQ10.865

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PANCREAS_BETA_CELLS0.360Cobimetinib— uncovered
MYOGENESIS0.310Inavolisib— uncovered
KRAS_SIGNALING_DN0.270Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.240Inavolisib— uncovered
UV_RESPONSE_DN0.220Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.200Inavolisib— uncovered
COAGULATION0.190Binimetinib— uncovered
ESTROGEN_RESPONSE_EARLY0.190Inavolisib— uncovered
HEDGEHOG_SIGNALING0.170Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.170Inavolisib— uncovered
APICAL_JUNCTION0.160Inavolisib— uncovered
APICAL_SURFACE0.150Temsirolimus— uncovered
HYPOXIA0.140Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.140Inavolisib— uncovered
NOTCH_SIGNALING0.120Inavolisib— uncovered
P53_PATHWAY0.100Idelalisib— uncovered
ANGIOGENESIS0.080Remibrutinib— uncovered
ESTROGEN_RESPONSE_LATE0.080Idelalisib— uncovered
ANDROGEN_RESPONSE0.070Inavolisib— uncovered
FATTY_ACID_METABOLISM0.070Inavolisib— uncovered